Biotech Vertex Pharmaceuticals stock tumbled on news of disappointing drug data. CEO Reshma Kewalramani paid nearly $4 ...

Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

The heritage British brand has been revived by a chairman whose impressive career before watchmaking includes a three-year ...

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...